Received Dec 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 8Z283 | — |
Drug dose administration interval too short; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 73-year-old male patient who received HAB (Twinrix) (batch number 8Z283, expiry date 25-FEB-2028) for prophylaxis. Previously administered products included Twinrix (1st dose of vaccine received on 08-Jun-2025) and Twinrix (2nd dose of vaccine received on 07-Jul-2025). On 03-DEC-2025, the patient received the 3rd dose of Twinrix. On 03-DEC-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: Drug dose administration interval too short). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 03-DEC-2025 The pharmacist asked about guidance for the vaccine series of Twinrix. The patient had been vaccinated as 1st dose on 08-JUN-2025, 2nd dose on 07-JUL-2025 and 3rd on 03-DEC-2025. The patient had wanted to know if the 6 months period was equal to 180 days and if the third dose had been valid. The batch number was not provided upon follow up with the reporter.